Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN versus SPECTAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN versus SPECTAZOLE.
DIFLUCAN vs SPECTAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Econazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing cell membrane permeability.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
Apply a thin layer to affected area once daily for 4-4 weeks; duration depends on indication.
None Documented
None Documented
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Terminal elimination half-life is approximately 24-30 hours in patients with normal renal function, allowing once-daily dosing.
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Primarily renal: approximately 70% of an oral dose is excreted unchanged in urine; biliary/fecal excretion accounts for ~20%, with the remainder as metabolites.
Category C
Category C
Antifungal
Antifungal